据财报，第三季度亏损总额、归母净亏损、归母扣非净亏损较上年同期增加，主要是由于本年同期账面 确认的未实现汇兑收益较上年有所下降所致。而前三季度亏损收窄则主要是由于营业收入大幅增加：即 奥布替尼销售量持续增加及与Prolium达成授权许可的首付款确认相关收入所致。 但公司第三季度亏损额扩大，第三季度公司实现营业收入3.84亿元，同比上升38.09%；归母净利润亏损 3432万元，去年同期亏损1357万元；扣非归母净利润亏损5308万元，去年同期亏损1451万元。 财报显示，诺诚健华研发投入占公司营收比例较高，该数据于今年前三季度为60.61%，较上年同期减 少27.53个百分点。此外，前三季度公司毛利率为88.8%，比上年同期的86.0%提高了2.8个百分点。 诺诚健华表示，报告期营收及药品销售收入变化主要是第三季度及前三季度营业收入大幅增加所致，一 方面奥布替尼销售量持续增加；另一方面公司与Prolium达成授权许可的首付款确认相关收入。 数据显示，作为诺诚健华核心产品，奥布替尼（宜诺凯 ）销售收入持续增长，前三季度共实现其销售 收入10.10亿元，同比增长45.77%。 11月13日，诺诚健华公布2025年 ...

Core Viewpoint - The company, Nocare Biopharma, reported significant growth in revenue and improvements in gross margin for the first nine months of 2025, driven by the sales of its core product, Obatuzumab, and a licensing agreement with Prolium Bioscience Inc [2][3]. Financial Performance - Total revenue for the first nine months of 2025 reached 1.115 billion RMB, representing a year-on-year increase of 59.85% [2]. - The gross margin improved to 88.8%, up from 86.0% in the same period last year, an increase of 2.8 percentage points [2]. - The net loss for the same period was 72 million RMB, a reduction of 74.78% compared to the previous year [2]. Product Performance - Sales revenue from the core product, Obatuzumab, amounted to 1.010 billion RMB in the first nine months of 2025, marking a year-on-year growth of 45.77% [3]. - In April 2025, Obatuzumab received approval for a new indication for first-line treatment of chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) in adult patients [3]. - Obatuzumab is the first and only BTK inhibitor approved in China for the MZL indication and has been included in multiple recommendations in the latest CSCO lymphoma treatment guidelines [3]. Cash Position - As of September 30, 2025, the company held approximately 7.759 billion RMB in cash and cash equivalents, which supports the acceleration of its pipeline projects [4].

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688428 证券简称：诺诚健华 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 公司董事会及董事、高级管理人员保证季度报告内容的真实、准确、完整，不存在虚假记载、误导性陈 述或重大遗漏，并承担个别和连带的法律责任。 公司负责人、主管会计工作负责人及会计机构负责人（会计主管人员）保证季度报告中财务信息的真 实、准确、完整。 第三季度财务报表是否经审计 □是√否 管理层业绩评述 诺诚健华医药有限公司（以下简称"公司"）管理层评论说："公司是一家以卓越的自主研发能力为核心 驱动力的高科技创新生物医药企业，拥有全面的研发、生产和商业化能力，专注于肿瘤和自身免疫性疾 病等存在巨大未满足临床需求的领域，在全球市场内开发具有突破性潜力的同类首创或同类最佳药物。 2025年1-9月公司总营业收入11.15亿元，比上年同期增长59.85%，毛利率为88.8%，比上年同期的86.0% 提高了2.8个百分点。营业收入与毛利率的高速增长主要为核心产品奥布替尼（宜诺凯?） ...

诺诚健华医药有限公司管理层评论说：公司是一家以卓越的自主研发能力为核心驱动力的高科技创新生 物医药企业，拥有全面的研发、生产和商业化能力，专注于肿瘤和自身免疫性疾病等存在巨大未满足临 床需求的领域，在全球市场内开发具有突破性潜力的同类首创或同类最佳药物。 格隆汇11月13日丨诺诚健华(09969.HK)公告，2025年1-9月公司总营业收入11.15亿元，比上年同期增长 59.85%，毛利率为88.8%，比上年同期的86.0%提高了2.8个百分点。营业收入与毛利率的高速增长主要 为核心产品奥布替尼(宜诺凯)销售收入持续增长以及公司与Prolium Bioscience Inc.(以下简称"Prolium") 达成授权许可的首付款所致。公司2025年1-9月的净亏损为0.72亿元，比上年同期亏损收窄74.78%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 海外監管公告 本公告乃百濟神州有限公司（BeOne Medicines Ltd., 「本公司」）根據香港聯合交易 所有限公司證券上市規則第13.10B條作出。 茲載列本公司於上海證券交易所網站刊發的《百濟神州有限公司2025年第三季度 報告》，僅供參閱。 承董事會命 百濟神州有限公司 主席 歐雷強先生 香港，2025年11月12日 於本公告日期，本公司董事會包括主席兼執行董事歐雷強先生、非執行董事 王曉東博士，以及獨立非執行董事Olivier Brandicourt博士、Margaret Han Dugan 博士、Michael Goller先生、Anthony C. Hooper先生、Ranjeev Krishana先生、 Alessandro Riva博士、Corazon (Corse ...

生物医药研发是一场九死一生的长征。 来源丨 投中网 在攀登产业珠峰的征途上，创业者是孤独的勇士，亦是需要灯塔的航船。 一种声音，一份力量。「登峰前沿·大家说」系列专题，汇聚由浦东科创集团与投中信息联合发起的"浦 东科创-海望登峰（二期）CEO特训营"创业者的真实表达。聆听他们的创业独白，见证他们的成长突 破，一同亲历新一代产业领袖的思考与蜕变。 将投中网设为"星标⭐"，第一时间收获最新推送 从CRO到创业者 许杰的职业生涯始于国内最大的CRO公司。在那里，他参与了早期平台搭建、质量体系建设和客户拓 展等全方位工作。"后来有机会参与公司新赛道的开拓工作，在这个过程中，我发现整个市场对于疾病 模型的需求非常多样。" 生物医药研发是一场九死一生的长征。据统计，一款新药从研发到上市平均需要10-15年时间，耗资数 十亿美元，而成功率不足10%。其中，临床前研究阶段的疾病模型是否精准，直接关系到药物后续研 发的成败。 以数百种疾病模型，构建新药研发的基石。从大小鼠到食蟹猴，许杰与他创立的精诚智研，已为上百家 药企提供专业服务。这家立足上海张江、布局海南的"模型工厂"，正将他的蓝图变为现实。 浦东i42J SPINNOT ...

Core Viewpoint - Jindike experienced a significant stock price increase, closing at 24.97 yuan per share, up 19.99%, marking its second consecutive trading limit up, with related flu concept stocks also rising [1] Company Overview - Jindike's main business includes research and production in biotechnology, particularly in the development of vaccines and related biological products [1] - The company is actively advancing its research projects to meet market demands, as evidenced by its ongoing Phase III clinical trials for the quadrivalent influenza virus split vaccine for children [1] Financial Performance - In the third quarter, Jindike reported a total R&D expenditure of 17.93 million yuan, which accounted for 25.21% of its operating revenue [1] - The increase in R&D expenses is primarily attributed to the Phase III clinical trials for the quadrivalent influenza virus split vaccine for children, indicating a year-on-year rise in R&D investment [1]

Core Viewpoint - Baili Tianheng has announced the launch of its H-share global public offering, marking a significant step in its internationalization strategy and aiming to enhance its position as a leading multinational pharmaceutical company in the oncology sector [1][2]. Group 1: H-share Offering Details - The company plans to issue 8,634,300 shares, with 863,500 shares allocated for public offering in Hong Kong and 7,770,800 shares for international offering [1]. - The price range for the H-share issuance is set between 347.50 HKD and 389.00 HKD, with the public offering starting on November 7, 2025, and expected to conclude by November 12, 2025 [1]. - Major investment banks, including Goldman Sachs, J.P. Morgan, and CITIC Securities, are acting as joint sponsors for the offering [1]. Group 2: Strategic Partnerships and Market Position - The offering has attracted cornerstone investors, including strategic partner Bristol-Myers Squibb (BMS) and several top-tier investment institutions, indicating strong market confidence [2]. - Baili Tianheng aims to leverage its innovative research capabilities in the field of oncology, focusing on unmet clinical needs and aspiring to achieve global commercialization by 2029 [2]. Group 3: Research and Development Capabilities - The company has established R&D centers in the U.S. and China, focusing on early product development and subsequent clinical research [3]. - Baili Tianheng has developed a leading innovative drug R&D platform and is currently conducting nearly 90 clinical trials globally, including 15 Phase III trials in China and 10 in the U.S. [3]. Group 4: Key Drug Developments - The drug Iza-bren, a first-in-class EGFR×HER3 bispecific ADC, is in Phase III clinical trials and has shown promising interim results, with plans for commercialization in China expected next year [6][7]. - Another significant drug, T-Bren, targeting HER2, is undergoing 14 clinical trials, demonstrating strong anti-tumor efficacy across various cancer types [8]. Group 5: Strategic Collaborations - In December 2023, Baili Tianheng entered a strategic collaboration with BMS, involving an upfront payment of 800 million USD and a potential total deal value of up to 8.4 billion USD, setting a record in the ADC field [9].

Group 1 - The company signed a technology transfer contract with Nanjing Gulou Hospital for the transfer of technical secrets related to NK cell-specific antigens and tumor-specific antigen cell connectors, with a total contract amount of 78.5 million yuan (including tax) [6][10] - The payment structure includes an upfront fee of 1.5 million yuan, progress rewards totaling 2.5 million yuan, and sales sharing up to 74.5 million yuan based on future sales [10][11] - The transaction is not classified as a related party transaction and does not constitute a major asset restructuring as per relevant regulations [6][7] Group 2 - The technology involved aims to enhance the targeting ability of NK cells against tumors without the need for transfection, which is a significant advancement in biomedicine [9] - The contract allows the company to develop, produce, and sell products based on the transferred technology globally and indefinitely [13] - The company anticipates that this transaction will help expand its pipeline in the biopharmaceutical sector, aligning with its long-term strategic goals [17] Group 3 - The company held a board meeting on October 24, 2025, where it approved the signing of the technology transfer contract [6][20] - The company plans to revise its articles of association and related meeting rules, including the cancellation of the supervisory board, which will be replaced by the audit committee of the board [20][21] - The proposed changes to the articles of association and meeting rules will be submitted for approval at the upcoming third extraordinary general meeting of shareholders [20]

Core Viewpoint - Baiaosaitu-B (02315) has seen a significant stock price increase, with a rise of over 12% during trading, currently up 9.5% at HKD 25.12, with a trading volume of HKD 11.11 million. The company has received approval from the China Securities Regulatory Commission (CSRC) for its IPO application on the STAR Market, aiming to raise approximately RMB 1.185 billion for various projects and working capital [1]. Group 1 - The company plans to use RMB 454 million for the construction of an early drug research and development service platform [1]. - RMB 316 million is allocated for the research and evaluation of antibody drugs [1]. - RMB 165 million is designated for preclinical and clinical research projects [1]. - RMB 250 million will be used to supplement working capital [1]. Group 2 - Baiaosaitu has recently announced collaborations with Germany's Tubulis and global technology leader Merck [1]. - The partnership with Tubulis involves the introduction of Baiaosaitu's self-developed fully human antibodies to advance the development and commercialization of ADC products, with the company set to receive an upfront payment and potential milestone payments based on development, regulatory, and commercialization achievements, along with a single-digit percentage of net sales [1]. - The collaboration with Merck focuses on developing antibody-conjugated lipid delivery solutions for nucleic acid drugs, such as antibody-conjugated lipid nanoparticles (LNP) [1].